Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 6, 2008, Pages 591-601

  Vermeer, N S ^b   Bajorek, B V ^a,b  

^a Pharmacy Building ^*  (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acute coronary syndromes; Antithrombotics; Evidence based pharmacotherapy; Secondary prevention; Utilization

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; EPROSARTAN; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; METOPROLOL; NADROPARIN; PERINDOPRIL; PRAVASTATIN; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; SOTALOL; TELMISARTAN; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; AUSTRALIA; BLEEDING; CHOLESTASIS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; FEMALE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; LIVER INJURY; MALE; MONOTHERAPY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; RISK REDUCTION; ST SEGMENT ELEVATION HEART INFARCTION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NEW SOUTH WALES; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEX FACTORS; TICLOPIDINE;

EID: 56049093923     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00950.x     Document Type: Article

References (42)

1. Australian Institute of Health and Welfare (2006) "Australia's health" 2006. AIHW cat. no. AUS 73. Canberra : AIHW.
2. Commonwealth Department of Health/Australian Institute of Health and Welfare (2000) National health priority areas report: cardiovascular health 1998. AIHW Cat. No. PHE 9. Canberra : AIHW.
3. Acute Coronary Syndrome Guidelines Working Group (2006) Guidelines for the management of acute coronary syndromes 2006. MJA, 184, S3 S30.
4. Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 361, 13 20.
5. Emmons KL, Taylor NR (2007) Contemporary issues in clopidogrel therapy: new evidence shaping clinical practice. Pharmacotherapy, 27, 553 563.
6. Steinhubl SR, Berger PB, Mann JT III. et al. (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 288, 2411 2420.
7. NSW Therapeutic Advisory Group (2007) Percentage of patients with acute coronary syndrome that are prescribed appropriate medication at discharge (indicator 5.1). Indicator for Quality Use of Medicines in Australian Hospitals, version 1, 70-71. Available at: http://www.ciap.health.nsw.gov.au/nswtag/ publications/QUMIndicators/5.1.pdf (accessed 14 November 2007).
8. Bertrand ME, Simoons ML, Fox KA et al. (2002) Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. European Heart Journal, 23, 1809 1840.
9. Van de Werf F, Ardissino D, Betriu A et al. (2003) Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. European Heart Journal, 24, 28 66.
10. Antman EM, Anbe DT, Armstrong PW et al. (2004) ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation, 110, 588 636.
11. Anderson JL, Adams CD, Antman EM et al. (2007) ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation, 116, e148 e304.
12. Fox KA, Goodman SG, Klein W et al. (2002) Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). European Heart Journal, 23, 1177 1189.
13. EUROASPIRE II Study Group (2001) Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. European Heart Journal, 22, 554 572.
14. Chew DP, Amerena J, Coverdale S et al. (2007) Current management of acute coronary syndromes in Australia: observations from the acute coronary syndromes prospective audit. Internal Medicine Journal, 37, 741 748.
15. Salomaa V, Paakkonen R, Hamalainen H, Niemi M, Klaukka T (2007) Use of secondary preventive medications after the first attack of acute coronary syndrome. European Journal of Cardiovascular Prevention and Rehabilitation, 14, 386 391.
16. Orford JL, Fasseas P, Melby S et al. (2004) Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. American Heart Journal, 147, 463 467.
17. Bradley EH, Herrin J, Elbel B et al. (2006) Hospital quality for acute myocardial infarction: correlation among process measures and relationship with short-term mortality. JAMA, 296, 72 78.
18. Ergin A, Muntner P, Sherwin R, He J (2004) Secular trends in cardiovascular disease mortality, incidence, and case fatality rates in adults in the United States. The American Journal of Medicine, 117, 219 227.
19. Australian Medicines Handbook Pty Ltd (2007 Australian Medicines Handbook., July 2007 edition. Adelaide : Australian Medicines Handbook Pty Ltd.
20. World Health Organisation (2007) International statistical classification of diseases and related health problems, 10th revision. ICD-10 Online. Available at: http://www.who.int/classifications/icd/ (accessed 6 November 2007).
21. Tang E, Wong CK, Wilkins G et al. (2005) Use of evidence-based management for acute coronary syndrome. The New Zealand Medical Journal, 118, U1678.
22. Rothberg MB, Celestin C, Fiore LD, Lawler E, Cook JR (2005) Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Annals of Internal Medicine, 143, 241 250.
23. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329 1339.
24. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324, 71 86.
25. Cheng JW (2007) Pharmacoeconomic analysis of clopidogrel in secondary prevention of coronary artery disease. Journal of Managed Care Pharmacy, 13, 326 336.
26. Yusuf S, Zhao F, Mehta SR et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The New England Journal of Medicine, 345, 494 502.
27. Sabatine MS, Cannon CP, Gibson CM et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. The New England Journal of Medicine, 352, 1179 1189.
28. Bottorff MB, Nutescu EA, Spinler S (2007) Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. Pharmacotherapy, 27, 1145 1162.
29. Daemen J, Wenaweser P, Tsuchida K et al. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 369, 667 678.
30. McFadden EP, Stabile E, Regar E et al. (2004) Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet, 364, 1519 1521.
31. Ho PM, Peterson ED, Wang L et al. (2008) Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA, 299, 532 539.
32. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. Journal of the American College of Cardiology, 48, 2584 2591.
33. Eisenstein EL, Anstrom KJ, Kong DF et al. (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA, 297, 159 168.
34. Grines CL, Bonow RO, Casey DE Jr. et al. (2007) Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Journal of American College of Cardiology, 49, 734 739.
35. Wong CK, Newby LK, Bhapker MV et al. (2007) Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to yield maximum protection from ischemic heart events postacute coronary syndromes trials. Am Heart J, 154, 313 321.
36. Scott IA, Duke AB, Darwin IC, Harvey KH, Jones MA (2005) Variations in indicated care of patients with acute coronary syndromes in Queensland hospitals. The Medical Journal of Australia, 182, 325 330.
37. Alexander KP, Roe MT, Chen AY et al. (2005) Evolution in cardiovascular care for elderly patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. Journal of the American College of Cardiology, 46, 1479 1487.
38. Roe MT, Parsons LS, Pollack CV Jr. et al. (2005) Quality of care by classification of myocardial infarction: treatment patterns for ST-segment elevation vs non-ST-segment elevation myocardial infarction. Archives of Internal Medicine, 165, 1630 1636.
39. Eikelboom JW, Hirsh J (2007) Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. Journal of Thrombosis and Haemostasis, 5 (Suppl 1 255 263.
40. Bertrand ME, Legrand V, Boland J et al. (1998) Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation, 98, 1597 1603.
41. Connolly S, Pogue J, Hart R et al. (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet, 367, 1903 1912.
42. Lip GYH, Karpha M (2006) Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention. CHEST, 130, 1823 1827.